Exabis Library
Welcome to the e-CCO Library!
P360 Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicentre study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P360: A randomised, assessor-blinded, multicentre trial comparing the efficacy, safety, and tolerability of a new tailored dosing regimen to day-before dosing regimen of colon cleansing agent used before colonoscopy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P360: Aggressive Inflammatory Bowel Disease is associated to Hermansky-Pudlak Syndrome: Characterization of a Puerto Rican Cohort
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P360: Inflammatory microheterogeneity in ulcerative colitis: implications for microscopic assessment of disease activity
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P360: Role of intestinal ultrasound scores in the diagnosis of post-operative recurrence in Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P360: The correlation between ophthalmological posterior segment findings and disease severity in patients with inflammatory bowel disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P360: Trough levels and antibodies to ustekinumab are not correlated to response to ustekinumab treatment in Crohn's disease patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P360: TrueColours ulcerative colitis (TCUC): Will patients with UC complete digital questionnaires in real-time?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P361 The effect of immunomodulators and other factors on the persistence of biological agents for Crohn’s disease and ulcerative colitis: data from the Australian population-based registry
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P361: Adherence to faecal calprotectin test in patients with inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P361: Laboratory criteria of infliximab therapy inefficiency in children with IBD
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P361: Machine learning models at week 6 of vedolizumab therapy for ulcerative colitis can predict week 52 corticosteroid free endoscopic remission
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P361: No increased postoperative risk of venous thromboembolism in patients with Ulcerative Colitis undergoing colectomy after tofacitinib exposure
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P361: Patterns of use and durability of initial and sequential biological agents in a large Paediatric inflammatory bowel disease observational cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P361: PREPARE-IBD: Physician Responses to disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease during the COVID-19 pandemic: A multicentre cohort analysis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P361: Risk of persistent gastrointestinal inflammation after treatment with immune checkpoint inhibitors
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn’s disease and ulcerative colitis (PACIFIC)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P362: Anti-virus treatment against CMV in patients with ulcerative colitis by the PCR monitoring for mucosal CMV-DNA
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P362: Faecal calprotectin is an early predictor of endoscopic response and histological remission after the start of vedolizumab
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P362: Influence of HLA DQA1*05 genotype in patients with inflammatory bowel disease and Anti-TNF treatment with proactive therapeutic drug monitoring.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM